Table 1.
Summary of characteristics of HIV-infected patients with advanced HCV-related cirrhosis at baseline.
| Characteristics | Data |
|---|---|
| No. | 50 |
| Gender (male) | 39 (78%) |
| Age (years) | 52.2 (48.8; 54.1) |
| Smoker | |
| Never | 6 (12.2%) |
| Previously (≥6 months) | 12 (24.5%) |
| Currently | 31 (63.3%) |
| Alcohol intake | |
| Never | 21 (42%) |
| Previously (≥6 months) | 24 (48%) |
| Currently | 5 (10%) |
| IVDU | |
| Never | 12 (24%) |
| Previously (≥6 months) | 38 (76%) |
| Currently | 0 (0%) |
| Treatments | |
| Statins | 8 (16%) |
| Previous IFNα therapy | 23 (46%) |
| DAAs regimens | |
| Sofosbuvir + Ledipasvir | 20 (40%) |
| Sofosbuvir + Daclatasvir | 14 (28%) |
| Sofosbuvir + Daclatasvir + Simeprevir | 3 (6%) |
| Sofosbuvir + Simeprevir | 10 (20%) |
| Ombitasvir + Paritaprevir + Ritonavir + Dasabuvir | 3 (6%) |
| Antiretroviral therapy | |
| NRTI + NNRTI-based | 7 (14.3%) |
| NRTI + II-based | 24 (49%) |
| NRTI + PI-based | 6 (12.2%) |
| PI + II + others-based | 4 (8.2%) |
| Others | 8 (16.3%) |
| HIV markers | |
| Prior AIDS | 18 (36%) |
| Nadir CD4+ T-cells (cells/mm3) | 114.7 (70; 182) |
| Nadir CD4+ <200 cells/mm3 | 35 (76.1%) |
| CD4+ T-cells (cells/mm3) | 439 (234; 721) |
| CD4+ <500 cells/mm3 | 30 (60%) |
| HCV markers | |
| HCV genotype | |
| 1 | 32 (65.3%) |
| 3 | 7 (14.3%) |
| 4 | 10 (20.4%) |
| Log10 HCV-RNA (IU/mL) | 6.2 (5.7; 6.7) |
| HCV-RNA ≥ 850.000 IU/mL | 33 (66%) |
| Liver disease markers | |
| LSM (kPa) | 31.6 (23.4; 40.7) |
| <25 kPa | 16 (26.7%) |
| 25–40 kPa | 29 (48.3%) |
| ≥40 kPa | 15 (25%) |
| CTP | 5 (5; 6) |
| CTP ≥ 7 | 6 (10.3%) |
| HVPG (mmHg) | 16 (11; 18) |
| <16 mmHg | 15 (48.4%) |
| 16–20 mmHg | 11 (35.5%) |
| ≥20 mmHg | 5 (16.1%) |
| Plasma biomarkers | |
| Bacterial translocation | |
| LPS (EU/mL) | 0.9 (0.7; 1.2) |
| LBP (μg/mL) | 1 (0.6; 1.4) |
| sCD14 (μg/mL) | 2.1 (1.6; 3.2) |
| FABP-2 (ng/mL) | 0.4 (0.1; 0.7) |
| Inflammation | |
| IP-10 (a.u.) | 1,221.5 (865.3; 1,799.5) |
| MCP-1 (a.u.) | 493.8 (276.1; 684.1) |
| IL-8 (a.u.) | 117.8 (74.6; 185.8) |
| IL-1β (a.u.) | 15 (13; 27.6) |
| IL-18 (a.u.) | 988.5 (573.1; 1,670.9) |
| IL-6 (a.u.) | 65.3 (33.8; 156.3) |
| TNF-α (a.u.) | 9.8 (7.4; 12) |
| IL-1RA (a.u.) | 18 (13; 25.9) |
| sRANKL (a.u.) | 24.3 (19; 36.4) |
| OPG (a.u.) | 217.5 (158.5; 307) |
| Endothelial dysfunction | |
| sVCAM-1 (a.u.) | 10,747 (8,616.8; 12,142.3) |
| sICAM-1 (a.u.) | 107.8 (63.5; 163.1) |
| TNFR-I (a.u.) | 32 (20.4; 57.8) |
| Coagulopathy | |
| PAI-1 (a.u.) | 1,054.8 (808.6; 1,315.3) |
| D-dimer (a.u.) | 1,767.5 (653.4; 4,289.9) |
| Angiogenesis | |
| VEGF-A (a.u.) | 76 (57.6; 90.8) |
| sVEGF-R1 (a.u.) | 44.5 (32.4; 69.5) |
Statistics: Values are expressed as absolute number (percentage) and median (interquartile range).
HCV, hepatitis C virus; HIV, human immunodeficiency virus; IVDU, intravenous drug user; IFNα, interferon-alpha; DAAs, direct-acting antivirals; NRTI, nucleoside analog HIV reverse; NNRTI, non-nucleoside analog HIV reverse transcriptase inhibitor; PI, protease inhibitor; II, integrase inhibitor; AIDS, acquired immune deficiency syndrome; HCV-RNA, HCV plasma viral load; LSM, liver stiffness measures; CPT, Child-Pugh-Turcotte; KVPG, hepatic venous pressure gradient (mmHg); a.u., arbitrary units of fluorescence; sCD14, soluble CD14; LPS, lipopolysaccharide; FABP2, fatty acid-binding protein 2; LBP, lipopolysaccharide binding protein; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; TNF-α, tumor necrosis factor alpha; IP-10, IFN-γ-inducible protein 10; MCP1, monocyte chemoattractant protein-1; OPG, osteoprotegerin; sRANKL, soluble receptor activator of nuclear factor-kappa B ligand; sVCAM-1, soluble vascular cell adhesion molecule 1; sICAM-1, soluble intercellular cell adhesion molecule 1; sTNFR-1, soluble tumor necrosis factor receptor 1; PAI-1, plasminogen activator inhibitor-1; VEGF-A; vascular endothelial growth factor A; sVEGF-R1, soluble receptor1 for vascular endothelial growth factor.